Clinical Deep Dive
Understanding Dry Eye Disease
Dry eye affects 16.4 million diagnosed Americans — and up to 50 million when undiagnosed cases are included. The condition is chronic, progressive, and profoundly impacts quality of life. Yet the vast majority of sufferers rely on temporary fixes like artificial tears. There is a better way.
A Screen-Driven Epidemic
Digital device use reduces blink rates by over 60%, and dry eye prevalence among screen workers ranges from 9.5% to 87.5% across studies (Al-Mohtaseb et al., 2021). San Francisco is uniquely exposed: the Bay Area ranks #1 in North America for tech talent concentration (CBRE, 2025), with 220,000+ tech workers averaging 10–12 hours of screen time daily.
The prevalence picture is stark and accelerating. Women face 2× the risk of men (8.8% vs. 4.5% prevalence) (Farrand et al., 2017), with postmenopausal women especially affected — 57% of menopausal women have dry eye disease (Contemporary OB/GYN). Age compounds the risk: approximately 70% of Americans over 60 have meibomian gland dysfunction (Amano & Inoue, 2017), the leading cause of evaporative dry eye. Contact lens wearers — 45 million Americans — face 4× higher risk (Stapleton et al., 2017).
Only about 2 million Americans are currently on prescription dry eye therapy, pointing to massive unmet need. Extrapolating national prevalence to the Bay Area's 7.75 million residents yields an estimated 527,000+ diagnosed patients locally.
“The average med spa visit costs $500–$700 — essentially identical to the median annual out-of-pocket dry eye spend of $500 — and both categories use identical financing mechanisms.”
The Clinical Evidence
IPL for dry eye has crossed the threshold from experimental to evidence-based. OptiLight by Lumenis became the first and only IPL device FDA-cleared specifically for dry eye management in April 2021. Publication volume has surged 1,300% in a decade, and at least six meta-analyses published between 2022 and 2025 confirm consistent efficacy.
The most rigorous systematic review (Peira et al., Acta Ophthalmologica, 2025, 13 RCTs) found IPL produces a clinically meaningful −16 OSDI point improvement versus placebo. Tear breakup time improved by approximately 2 seconds across multiple meta-analyses. A network meta-analysis (Chen et al., 2025) comparing IPL with LipiFlow across 12 RCTs and 969 patients found IPL demonstrated superior TBUT improvement (+2.08s vs. +0.67s for LipiFlow).
−16 OSDI Points
Symptom improvement vs. placebo (Peira et al., 2025, 13 RCTs)
90.2% Effective
IPL effective rate vs. 80% for warm compresses (Wang et al., 2023, 132 patients)
Zero Serious AEs
Six of ten studies measuring AEs reported zero events (Peira et al., 2025)
Superior to LipiFlow
IPL +2.08s TBUT vs. +0.67s for LipiFlow (Chen et al., 2025, 969 patients)
Beyond IPL: The Full Arsenal
IPL is the cornerstone, but a comprehensive dry eye practice offers a full treatment menu. Low-level light therapy (LLLT) uses 633nm red and 830nm near-infrared LEDs to stimulate mitochondrial function and reduce inflammation. Combined IPL + LLLT produced OSDI improvement from 44.4 to 25.4 (−43%) in a landmark 230-patient study (Stonecipher et al., 2019). A head-to-head RCT found LLLT alone produced greater symptom improvement than IPL alone (Giannaccare et al., 2023). LLLT works on all Fitzpatrick skin types, requires no coupling gel, and can be delegated to trained technicians.
Radiofrequency (RF) is gaining adoption for periocular MGD treatment, with studies showing significant OSDI reduction and TBUT improvement. Safe for all skin types. ZEST okra-based lid debridement at ~$75/treatment is an excellent entry-level, high-margin add-on. Xdemvy (lotilaner), the first FDA-approved Demodex blepharitis treatment (July 2023), addresses the ~25 million Americans with Demodex — a natural pharmaceutical complement to in-office procedures.
Why a Med Spa — Not a Traditional Clinic
The demographic profiles of med spa patients and dry eye sufferers converge with striking precision. Med spa patients are 88% female with a peak age of 35–54, and 33% earn over $100,000 annually (Brenton Way). Dry eye patients are 68% female (Farrand et al., 2017) with prevalence escalating sharply after age 35. The intersection — women aged 35–60 with household incomes above $75,000 — represents both the economic engine of medical aesthetics and the fastest-growing dry eye cohort.
The dual-use nature of IPL equipment is the linchpin: a single device treats both dry eye (medical) and skin conditions (aesthetic), maximizing equipment utilization and creating natural patient crossover. Multiple practices report that patients who receive dry eye IPL frequently upgrade to full-face treatment for an additional $300, or return specifically for cosmetic sessions after experiencing the aesthetic “side effects” of their medical treatment (Review of Optometric Business).
San Francisco has zero med spas offering dry eye IPL treatment — despite serving a population where roughly half of tech workers experience symptoms and the core med spa demographic overlaps almost perfectly with the fastest-growing dry eye patient cohort. The competitive gap is wide open.
“57% of optometrists have already implemented aesthetic services. The emerging subspecialty of ‘ocular aesthetics’ is no longer theoretical — it's a validated practice model.”
— Women In Optometry Survey
References
- Grand View Research — U.S. Dry Eye Syndrome Treatment Market Report
- Farrand et al. “Prevalence of Diagnosed Dry Eye Disease in the United States.” Am J Ophthalmol, 2017.
- Al-Mohtaseb et al. “The Relationship Between Dry Eye Disease and Digital Screen Use.” Clin Ophthalmol, 2021.
- Contemporary OB/GYN — Postmenopausal Women Show Higher Prevalence of Dry Eye Disease
- CBRE — San Francisco Bay Area Tech Talent Report, 2025
- Amano & Inoue. “Estimation of Prevalence of Meibomian Gland Dysfunction.” Cornea, 2017.
- Stapleton et al. “TFOS DEWS II Epidemiology Report.” Ocul Surf, 2017.
- Lumenis — FDA Approval for OptiLight IPL Device, 2021
- Peira et al. “IPL for MGD: Systematic Review and Meta-Analysis.” Acta Ophthalmologica, 2025.
- Chen et al. “Network Meta-Analysis: IPL vs LipiFlow.” Cont Lens Anterior Eye, 2025.
- Wang et al. “IPL vs Traditional Therapy for Dry Eye.” J Clin Med, 2023.
- Stonecipher et al. “Combined IPL and LLLT for Dry Eye.” Clin Ophthalmol, 2019.
- Giannaccare et al. “LLLT vs IPL for Dry Eye: RCT.” 2023.
- Brenton Way — Med Spa Marketing Stats & Trends
- Review of Optometric Business — Dry Eye Aesthetic Treatment Technology
- Women In Optometry — 57% of ODs Offering Aesthetic Services
Ready to learn more?
Whether you're a med spa owner exploring a partnership or a patient seeking relief — we'd love to talk.